Results 201 to 210 of about 13,784,502 (261)
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank
International Journal of Cancer, EarlyView.ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang +9 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT There is no study from Germany on the association between stage of lung cancer (LC) and patient characteristics. We aimed to compare advanced versus non‐advanced LC cases regarding indicators of healthcare utilization. Using claims data covering 20% of the German population, we included LC patients diagnosed between 2013 and 2019.
Josephine Küsel‐Kanbach +2 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır +32 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT People with HIV (PWH) are living longer, but contemporary data on non–AIDS‐defining cancers (NADCs) in Italy remain limited. We assessed incident cancers in a retrospective cohort of PWH in Milan, Italy, between January 2000 and December 2023. Follow‐up was grouped into 2000–2007, 2008–2015, and 2016–2023. Incidence rates (IRs) were calculated
Giacomo Pozza +14 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Tibolone, a synthetic steroid with estrogenic, progestogenic, and androgenic activity, is widely prescribed for menopausal symptoms, but its association with hepatocellular carcinoma (HCC) remains unclear. Using data from 117,271 women aged ≥ 45 years in the Korean National Health Insurance Service–Health Screening Cohort, we evaluated ...
Jimin Lee +9 more
wiley +1 more source